Dr Joël Richard is currently Head of Technical &Pharmaceutical Operations at MedinCell (Montpellier, France). He is leading all the pharmaceutical development and non-clinical pharmaco/toxico-kinetic activities of the company, specialized in the development of Long-Acting Injectables. (LAIs), using theproprietary technology BEPO®. Dr Richard has 30 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various Biotech and Pharma companies, such as: -Senior Vice President, Pharmaceutical Development –Peptides in Ipsen (France),-Vice President, Drug Product Development in Ipsen (France),-Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany),-Vice President Research, and Europe R&D Director at Ethypharm (France),-COO atMainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems. Since 1996, Dr Richard has focused his research activity on new formulation technologies and drug deliverysystems (such as microspheres, nanosystems, gelling systems, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. Dr Richard has graduated from Ecole Normale Supérieure (Cachan, France). He has got a PhD in Materials Science from University of Paris, France, and the “Habilitation à Diriger les Recherches” degree in Chemistry from University of Bordeaux I. He has published 68 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery systems, supercritical fluids, protein formulations, nanoparticles, etc.). He is the author of more than 140 international communications and 55 patent families.